Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05300724 · ClinicalTrials.gov registry record
An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration
A clinical trial of Age-related Macular Degeneration, sponsored by Genentech.
- Active
- Registry status
- 400
- Enrollment target
- 20
- Study locations
NCT05300724 is a study of Age-related Macular Degeneration that is active but no longer recruiting, run by Genentech. The registered enrollment target is 400 participants, below the 1,502-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT05300724, a study of Age-related Macular Degeneration, is active but no longer recruiting, sponsored by Genentech.
- ACTIVE NOT RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter prospective study in participants with intermediate age-related macular degeneration (iAMD). One primary objective of this study is to assess iAMD disease progression, by the timeline and rates of conversion for high-risk iAMD at baseline to more advanced atrophic AMD stages. The other primary objective of this observational study is to assess the feasibility of measuring the rate of photoreceptor loss as a potential clinical endpoint. The study will consist of an observation period of approximately 3 years (\~144 weeks) for participants.
Conditions Studied
Interventions
- OTHER No intervention
Study Locations (20)
California
- The Retina Partners - Encino
- Retina Consultants of Orange County - Fullerton
- Northern California Retina Vitreous Associates - Mountain View
- Retina Consultants, San Diego - Poway
- UC Davis Eye Center - Sacramento
- Retinal Consultants Medical Group - Sacramento
- Bay Area Retina Associates - Walnut Creek
Florida
- Advanced Research - Coral Springs
- Rand Eye Institute - Deerfield Beach
- National Ophthalmic Research Institute - Fort Myers
- Florida Eye Associates - Melbourne
Colorado
- Southwest Retina Consultants - Durango
- Eye Care Center of Northern Colorado PC - Longmont
Arkansas
- Retina Partners of Northwest Arkansas, PLLC - Springdale
Georgia
- Southeast Retina Center - Augusta
Illinois
- University Retina and Macula Associates, PC - Oak Forest
Indiana
- Raj K. Maturi, MD PC - Indianapolis
Iowa
- Wolfe Eye Clinic - West Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2027-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05300724
The ClinicalTrials.gov registry entry for NCT05300724 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,502-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (73% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT05300724 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT05300724 about?
NCT05300724 is a clinical study titled "An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration". This is a multicenter prospective study in participants with intermediate age-related macular degeneration (iAMD). One primary objective of this study is to assess iAMD disease progression, by the timeline and rates of conversion for high-risk iAMD at baseline to more advanced atrophic AMD stages. T...
What is the current status of trial NCT05300724?
This trial is currently active not recruiting. The enrollment target is 400 participants. The study started on 2022-05-27. Estimated completion is 2027-06-30.
What conditions does trial NCT05300724 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT05300724?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT05300724?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05300724 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
High Resolution Retinal Imaging
RECRUITING
-
Visual Remapping to Aid Reading With Field Loss
RECRUITING · NA
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
Effects of Goji vs. Fiber on Macular Degeneration
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.